Compile Data Set for Download or QSAR
Report error Found 67 Enz. Inhib. hit(s) with all data for entry = 11513
Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621998(US20230312542, Example 54)
Affinity DataKd: <1.00E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621993(US20230312542, Example 44)
Affinity DataKd: <1.00E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622037(US20230312542, Example 159)
Affinity DataKd: <1.00E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622021(US20230312542, Example 107)
Affinity DataKd: <1.00E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622022(US20230312542, Example 108)
Affinity DataKd: <1.00E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622023(US20230312542, Example 111)
Affinity DataKd: <1.00E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622033(US20230312542, Example 153)
Affinity DataKd: <1.00E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622034(US20230312542, Example 154)
Affinity DataKd: <1.00E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622036(US20230312542, Example 158)
Affinity DataKd: <1.00E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622029(US20230312542, Example 144)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622031(US20230312542, Example 148)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622032(US20230312542, Example 150)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622026(US20230312542, Example 139)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622027(US20230312542, Example 140)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622028(US20230312542, Example 141)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621974(US20230312542, Example 1)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621975(US20230312542, Example 6)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621976(US20230312542, Example 14)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622035(US20230312542, Example 155)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622013(US20230312542, Example 84)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622014(US20230312542, Example 89)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622015(US20230312542, Example 90)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622016(US20230312542, Example 91)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622009(US20230312542, Example 78)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622010(US20230312542, Example 79)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622011(US20230312542, Example 80)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622012(US20230312542, Example 81)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622024(US20230312542, Example 112)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622017(US20230312542, Example 93)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622019(US20230312542, Example 97)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621997(US20230312542, Example 53)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621999(US20230312542, Example 61)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622000(US20230312542, Example 62)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621994(US20230312542, Example 48)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621995(US20230312542, Example 49)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621996(US20230312542, Example 51)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622006(US20230312542, Example 74)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622007(US20230312542, Example 75)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622008(US20230312542, Example 76)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622001(US20230312542, Example 63)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM622002(US20230312542, Example 64)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621981(US20230312542, Example 19)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621982(US20230312542, Example 20)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621983(US20230312542, Example 21)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621984(US20230312542, Example 22)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621977(US20230312542, Example 15)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621978(US20230312542, Example 16)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621979(US20230312542, Example 17)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621980(US20230312542, Example 18)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandPNGBDBM621989(US20230312542, Example 30)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Displayed 1 to 50 (of 67 total ) | Next | Last >>
Jump to: